medRxiv preprint doi: https://doi.org/10.1101/2023.11.20.23298785; this version posted November 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

#### Safety and immunogenicity of booster vaccination and fractional dosing 1 with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants 2

3

Catherine Riou<sup>1,2</sup>\*, Jinal N Bhiman<sup>3,4</sup>\*, Yashica Ganga<sup>5</sup>\*, Shobna Sawry<sup>6</sup>\*, Frances 4

- Ayres<sup>3,4</sup>, Richard Baguma<sup>1</sup>, Sashkia R Balla<sup>3,4</sup>, Ntombi Benede<sup>1</sup>, Mallory Bernstein<sup>5</sup>, Asiphe 5
- S Besethi<sup>1</sup>, Sandile Cele<sup>5</sup>, Carol Crowther<sup>3,4</sup>, Mrinmayee Dhar<sup>6</sup>, Sohair Geyer<sup>1</sup>, Katherine 6
- Gill<sup>7</sup>, Alba Grifoni<sup>8</sup>, Tandile Hermanus<sup>3,4</sup>, Haajira Kaldine<sup>3,4</sup>, Roanne S Keeton<sup>1</sup>, Prudence 7
- Kgagudi<sup>3,4</sup>, Khadija Khan<sup>5,9</sup>, Erica Lazarus<sup>10</sup>, Jean Le Roux<sup>6</sup>, Gila Lustig<sup>11</sup>, Mashudu 8
- Madzivhandila<sup>3</sup>, Siyabulela FJ Magugu<sup>1</sup>, Zanele Makhado<sup>3,4</sup>, Nelia P Manamela<sup>3,4</sup>, Qiniso 9
- Mkhize<sup>3,4</sup>, Paballo Mosala<sup>1</sup>, Thopisang P Motlou<sup>3,4</sup>, Hygon Mutavhatsindi<sup>1</sup>, Nonkululeko B 10
- Mzindle<sup>3</sup>, Anusha Nana<sup>10</sup>, Rofhiwa Nesamari<sup>1</sup>, Amkele Ngomti<sup>1</sup>, Anathi A Nkayi<sup>1</sup>, Thandeka 11
- P Nkosi<sup>7</sup>, Millicent A Omondi<sup>1</sup>, Ravindre Panchia<sup>10</sup>, Faeezah Patel<sup>6</sup>, Alessandro Sette<sup>8,12</sup>, 12
- Upasna Singh<sup>11</sup>, Strauss van Graan<sup>3,4</sup>, Elizabeth M. Venter<sup>3,4</sup>, Avril Walters<sup>1</sup>, Thandeka 13
- Moyo-Gwete<sup>3,4</sup>, Simone I. Richardson<sup>3,4</sup>, Nigel Garrett<sup>11,13</sup>, Helen Rees<sup>6</sup>, Linda-Gail Bekker<sup>7</sup>, 14
- Glenda Gray<sup>14</sup>, Wendy A. Burgers<sup>1,2</sup>\*, Alex Sigal<sup>5,9,11</sup>\*, Penny L Moore<sup>3,4,11</sup>\*, Lee Fairlie<sup>6</sup>\* 15
- 16

#### 17 Affiliations:

- <sup>1</sup> Institute of Infectious Disease and Molecular Medicine, Division of Medical Virology, 18
- Department of Pathology, University of Cape Town, Observatory, South Africa 19
- 20 <sup>2</sup> Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town,
- 21 Observatory, South Africa
- <sup>3</sup> SA MRC Antibody Immunity Research Unit, School of Pathology, University of the 22
- Witwatersrand, Johannesburg, South Africa 23
- 24 <sup>4</sup> Center for HIV and STIs, National Institute for Communicable Diseases of the National
- 25 Health Laboratory Services, Johannesburg, South Africa
- <sup>5</sup> Africa Health Research Institute, Durban, South Africa. 26
- 27 <sup>6</sup> Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 28 South Africa
- 29 <sup>7</sup> The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
- <sup>8</sup> Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, California, USA 30
- <sup>9</sup> School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, 31
- Durban, South Africa. 32
- 33 <sup>10</sup> Perinatal HIV Research Unit, Faculty of Health Science, University of the Witwatersrand, 34 Johannesburg, South Africa.
- <sup>11</sup> Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, 35 36 Durban, South Africa.
- <sup>12</sup> Department of Medicine, Division of Infectious Diseases and Global Public Health, 37
- 38 University of California, San Diego (UCSD), La Jolla, California, USA
- <sup>13</sup> Department of Public Health Medicine, School of Nursing and Public Health, University of 39
- 40 KwaZulu-Natal, Durban, South Africa.
- <sup>14</sup> South African Medical Research Council, Cape Town, South Africa 41
- 42
- 43 \* These authors contributed equally
- Corresponding Author: Lee Fairlie (LFairlie@wrhi.ac.za) 44
- 45
- 46 Abstract: 251 words, Full text: 11,773 words, Reference: 58.
- Table: 1, Figures: 11, Supp tables: 2, Supp figure: 1. 47
- 48

#### 49 ABSTRACT

50 **Background.** We report the safety and immunogenicity of fractional and full dose

51 Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously

vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous

53 SARS-CoV-2 infection.

54 Methods. A total of 286 adults (with or without HIV) were enrolled >4 months after an

55 Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of

56 Ad26.COV2.S or BNT162b2 vaccine. B cell responses (binding, neutralization and antibody

57 dependent cellular cytotoxicity-ADCC), and spike-specific T-cell responses were evaluated at

baseline, 2, 12 and 24 weeks post-boost. Antibody and T-cell immunity targeting the Ad26

59 vector was also evaluated.

60 Results. No vaccine-associated serious adverse events were recorded. The full- and half-

dose BNT162b2 boosted anti-SARS-CoV-2 binding antibody levels (3.9- and 4.5-fold,

respectively) and neutralizing antibody levels (4.4- and 10-fold). Binding and neutralizing

antibodies following half-dose Ad26.COV2.S were not significantly boosted. Full-dose

64 Ad26.COV2.S did not boost binding antibodies but slightly enhanced neutralizing antibodies

65 (2.1-fold). ADCC was marginally increased only after a full-dose BNT162b2. T-cell responses

66 followed a similar pattern to neutralizing antibodies. Six months post-boost, antibody and T-

67 cell responses had waned to baseline levels. While we detected strong anti-vector immunity,

68 there was no correlation between anti-vector immunity in Ad26.COV2.S recipients and spike-

69 specific neutralizing antibody or T-cell responses post-Ad26.COV2.S boosting.

70 **Conclusion.** In the context of hybrid immunity, boosting with heterologous full- or half-dose

71 BNT162b2 mRNA vaccine demonstrated superior immunogenicity 2 weeks post-vaccination

compared to homologous Ad26.COV2.S, though rapid waning occurred by 12 weeks post-

73 boost.

Department of Health (SA DoH).

76

Trial Registration: South African National Clinical Trial Registry (SANCR): DOH-27-012022 7841; Funding: South African Medical Research Council (SAMRC) and South African

## 77 Introduction

78 The development of vaccines against SARS-CoV-2 was unparalleled, with numerous 79 platforms suited to rapid production dominating use in initial vaccination programs globally. 80 This included adenovirus-vectored vaccines, such as the Janssen Ad26.COV2.S, replicationincompetent adenovirus 26 vectored SARS-CoV-2 spike protein vaccine. This vaccine is 81 82 registered as a single dose, with subsequent boosters recommended. This was the first vaccine available nationally in South Africa, and health care workers, and later other essential 83 84 workers, were offered this vaccine as part of the Sisonke trial [1]. The mRNA-based Pfizer BNT162b2 Comirnaty vaccine became available in South Africa subsequently as part of the 85 national vaccine rollout. 86

The emergence of SARS-CoV-2 variants of concern (VOCs) including the Beta, Delta and 87 Omicron variants reduced vaccine effectiveness against infection [2-6]. All vaccines based on 88 the sequence of the SARS-CoV-2 ancestral spike, including the Janssen Ad26.COV2.S and 89 the Pfizer Comirnaty BNT162b2 vaccines, elicited dramatically lower titers of neutralizing 90 91 antibodies against the Omicron subvariants [4, 7-20]. Vaccines incorporating Omicron 92 subvariant sequences [21] are not available in South Africa. However, the main driver of increased neutralizing capacity against Omicron variants is hybrid immunity, which is the 93 combination of vaccine and infection elicited immunity. Population studies in SA showed 94 95 seroprevalence levels in excess of 95% by the end of the Omicron BA.1 Wave [22]. 96 However, given the waning of humoral and cellular immunity over time, COVID-19 vaccine 97 boosting may be beneficial, especially in individuals at high risk for severe disease. The choice of booster, timing and dose remain largely dependent on regulatory and national 98 considerations, including fiscal constraints and capacity of the health care system. Several 99 100 studies have demonstrated a more robust humoral and cellular immune response with a heterologous boost compared to a homologous boost, in particular when boosting is with an 101 mRNA vaccine [12, 15, 23]. A further consideration is that due to pressure on vaccine 102 103 development, cost and equitable access, which are significantly impacted if multiple boosters

are needed, strategies such as fractional dosing should be considered. Fractional dosing has 104 previously been used with other vaccines such as yellow fever [24]. 105 106 South Africa is burdened by more HIV infections than any other country in the world, with 107 approximately 8 million people living with HIV (PLWH) [25, 26]. PLWH, especially those with low CD4 T-cell counts, have moderately worse COVID-19 outcomes [27-35]. This is 108 associated with lower and delayed neutralizing antibody titers in response to SARS-CoV-2 109 infection [19, 34, 36], more pronounced in PLWH with HIV viremia [19]. However, similar to 110 111 results reported for the AstraZeneca ChAdOx and the Pfizer BNT162b2 vaccines [37-41], there was no observed difference between PLWH and HIV-negative individuals in neutralizing 112 antibody titers against SARS-CoV-2 spike after Ad26.COV2.S vaccination [19, 36]. 113 Vaccines which use a viral vector to deliver the immunogen may be inhibited by pre-existing 114 immunity to the virus on which the vector is based [42, 43]. In addition to eliciting immunity to 115 116 the vaccine target, vaccination with an adenovirus vectored vaccine has been shown to elicit neutralizing antibody and T-cell immunity to the vector itself [44-46]. This may reduce the 117 118 ability of repeated doses of the vectored vaccine to infect cells or reduce vaccine vector-119 infected cell survival. The degree of elicited anti-vector immunity could therefore potentially determine the effectiveness of vectored immunization in a population with previous immunity 120 to the virus on which the vector is based, or effectiveness if the vaccinees have been 121 122 previously immunized with the same vector. However additional factors, including transgene 123 persistence as well as local or systemic persistence may also impact the effectiveness of viral 124 vectored vaccines. In this study, we evaluated the immunogenicity and safety of diverse boost strategies after 125 primary Ad26.COV2.S vaccination. We tested fractional and full dose heterologous and 126

128 effects of HIV status, and degree of anti-adenovirus 26 vector immunity before and after

homologous booster Ad26.COV2.S and BNT162b2 vaccinations. We also determined the

127

boosting. We observed that heterologous boosting of Ad26.COV2.S with the BNT162b2

mRNA vaccine was the most effective regimen to transiently enhance humoral and T-cell
immunity and HIV status did not have a substantial effect on the outcome. We show that

- 132 homologous boosting with Ad26.COV2.S occurred in the context of high anti-Ad26 vector
- immunity. Although, Ad26.COV2.S gave a weak increase in antibody and cellular responses
- 134 against SARS-CoV-2 spike, we observed no correlation between vaccine response and anti-
- Ad26 neutralizing antibody levels, as previously reported [47, 48].

## 136 Methods and Materials

Study Design and Participants. This study, Booster After Sisonke Study (BaSiS), is an 137 ongoing phase 2, randomized, open-label trial to evaluate the safety and immunogenicity of a 138 booster vaccination in participants who received a single Ad26.COV2.S vaccine through the 139 Sisonke phase 3B implementation study or via the South African National Department of 140 Health COVID-19 vaccine rollout. Participants were healthy adults, who met study eligibility 141 criteria and included participants with well-controlled comorbidities, except for HIV infection 142 143 where there were no immunological or virological exclusions. Full eligibility criteria are provided in the protocol. We aimed to enrol at least one third of participants as PLWH and at 144 least 10% >55 years of age. Participants were included if they had no SARS-CoV-2 infection 145 at least 28 days prior to randomization. The study was conducted at four research sites in 146 South Africa, two in Johannesburg, one in Durban and one in Cape Town. 147 148 **Randomization.** Participants were randomized 1:1:1:1 to one of four booster vaccinations including: Arm A: full-dose Ad26.COV2.S (5x10<sup>10</sup> vp/mL, 0.25 mL); Arm B: half-dose 149 150 Ad26.COV2.S (2.6x10<sup>10</sup> vp/mL, 0.13 mL); Arm C: full-dose BNT162b2 Comirnaty vaccine 151 (30mcg) and Arm D: half-dose BNT162b2 Comirnaty vaccine (15mcg). No masking was 152 required since the study was open-label. Procedures. Study visits took place at baseline (randomization), 2 weeks, 12 weeks and 24 153 154 weeks. At each visit, medical history, COVID-19 infection history (symptoms or positive test) 155 and vaccination history (COVID-19 vaccine or other vaccination) was taken, followed by a 156 targeted clinical examination when necessary. At the baseline visit, participants received a single booster vaccination, as per the randomization arm. Diary cards were issued and 157 participants were trained to collect data up to 7 days post booster. Telephonic contact at day 7 158 159 was conducted to enquire about severity or ongoing nature of reactogenicity. Blood samples were drawn at each visit and included HIV testing at baseline (in all except those known to be 160 PLWH), CD4 count and HIV viral load (in PLWH), full blood count (BL, W2 and additional visits 161 in PLWH), D-dimers (BL and W2). A nasopharyngeal swab for SARS-CoV-2 PCR was 162

conducted at baseline. Interim visits were held for any safety concerns or if a participant had 163 COVID-19 symptoms or a positive SARS-CoV-2 PCR or antigen test outside of the study. 164 Safety. Reactogenicity was collected and graded according to criteria included in Food and 165 Drug Administration (FDA) "The Guidance for Industry: Toxicity Grading Scale for Healthy 166 Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" [49]. All grade 167 3 reactogenicity events, SAEs, SUSARs and adverse drug reactions were reported. A Data 168 Safety and Monitoring Committee was established to evaluate protocol-defined safety events 169 170 and immunogenicity data.

171

### 172 Immunogenicity

## 173 Live virus neutralization assay

Live virus neutralization assay was performed as previously described in our previous work [4, 174 6, 18]. Briefly, ACE2-expressing H1299-E3 (CRL-5803, ATCC) cells were seeded at 4.5×10<sup>5</sup> 175 cells per well and incubated for 18-20 h. After washing, the sub-confluent cell monolayer was 176 177 inoculated with 500 µL universal transport medium diluted 1:1 with filtered growth medium. 178 Cells were incubated for 1 h. Wells were then filled with 3 mL complete growth medium. After 4 days of infection (completion of passage 1), cells were trypsinized, centrifuged and 179 resuspended in 4 mL growth medium. Then, all infected cells were added to Vero E6 cells 180 181 (CRL-1586, ATCC). The coculture of ACE2-expressing H1299-E3 and Vero E6 cells was 182 incubated for 4 days. The viral supernatant from this culture (passage 2 stock) was used for 183 experiments.

H1299-E3 cells were plated at 30,000 cells/well 1 day pre-infection. Aliquots of cryo-preserved
plasma samples were heat-inactivated and clarified by centrifugation. Virus stocks were used

186 at approximately 50-100 focus-forming units per microwell and added to diluted plasma.

187 Antibody–virus mixtures were incubated for 1 h at 37°C. Cells were infected with 100 µL of the

virus–antibody mixtures for 1 h, then 100 µL of a RPMI 1640 (Sigma-Aldrich), 1.5%

189 carboxymethylcellulose (Sigma-Aldrich) overlay was added without removing the inoculum.

190 Cells were fixed 18 h post-infection. Foci were stained with a rabbit anti-spike monoclonal

antibody (0.5 µg/mL, BS-R2B12, GenScript) overnight at 4°C, washed and then incubated 191 with a horseradish peroxidase (HRP) conjugated goat anti-rabbit antibody (1 µg/mL, Abcam 192 193 ab205718) for 2 h. TrueBlue peroxidase substrate (SeraCare) was then added and incubated 194 for 20 min. Plates were imaged in an ImmunoSpot Ultra-V S6-02-6140 Analyzer ELISPOT instrument with BioSpot Professional built-in image analysis (C.T.L). All statistics and fitting 195 were performed using custom code in MATLAB v.2019b. Neutralization data were fit to: 196  $Tx=1/1+(D/ID_{50})$ . Tx is the number of foci normalized to the number of foci in the absence of 197 198 plasma on the same plate at dilution D and  $ID_{50}$  is the plasma dilution giving 50% 199 neutralization. FRNT<sub>50</sub> =  $1/ID_{50}$ . Values of FRNT<sub>50</sub> <1 are set to 1 (undiluted), the lowest measurable value. As, the most concentrated plasma dilution was 1:25,  $FRNT_{50}$  <25 were 200 extrapolated. To calculate confidence intervals,  $FRNT_{50}$  or fold-change in  $FRNT_{50}$  per 201 participant was log-transformed and arithmetic mean plus and minus two standard deviations 202 203 were calculated for the log transformed values. These were exponentiated to obtain the upper and lower 95% confidence intervals on the geometric mean FRNT<sub>50</sub> or the fold-change in 204 205 FRNT<sub>50</sub> geometric means. 206 Sequences of outgrown ancestral SARS-CoV-2 and the Omicron BA.5 subvariant have been

deposited in GISAID with accession EPI\_ISL\_602626.1 (ancestral, D614G) and

208 EPI\_ISL\_12268493.2 (Omicron/BA.5).

209

210 SARS-CoV-2 spike and nucleocapsid enzyme-linked immunosorbent assay (ELISA) 211 For ELISA, Hexapro SARS-CoV-2 full spike protein with the D614G substitution were expressed in Human Embryonic Kidney (HEK) 293F suspension cells by transfecting the cells 212 with the respective expression plasmid. After incubating for 6 days at 37°C, proteins were first 213 214 purified using a nickel resin followed by size exclusion chromatography. Relevant fractions were collected and frozen at -80°C until use. Two µg/mL of D614G spike or nucleocapsid 215 protein was used to coat 96-well, high-binding plates (Corning) and incubated overnight at 216 217 4°C. The plates were incubated in a blocking buffer consisting of 1x PBS, 5% skimmed milk 218 powder, 0.05% Tween 20. Plasma samples were diluted to 1:100 starting dilution in a blocking

buffer and added to the plates. IgG secondary antibody (Merck) was diluted to 1:3000 in
blocking buffer and added to the plates followed by TMB substrate (Thermofisher Scientific).
Upon stopping the reaction with 1 M H2SO4, absorbance was measured at 450 nm. For spike
ELISA, mAbs CR3022 was used as a positive control and Palivizumab was used as a
negative control.

224

# 225 Lentiviral pseudovirus production and neutralization assay

226 Virus production and pseudovirus neutralization assays were done as previously described.

227 Briefly, 293T/ACE2.MF cells modified to overexpress human ACE2 (provided by M. Farzan,

228 Scripps Research) were cultured in DMEM (Gibco) containing 10% FBS and 3 µg/mL of

puromycin at 37°C. Cell monolayers were disrupted at confluency by treatment with 0.25%

trypsin in 1 mM EDTA (Gibco). The SARS-CoV-2, Wuhan-1 spike, cloned into pCDNA3.1 was

231 mutated using the QuikChange Lightning Site-Directed Mutagenesis kit (Agilent Technologies)

and NEBuilder HiFi DNA Assembly Master Mix (NEB) to include D614G (wild-type) or lineage

233 defining mutations for Beta (L18F, D80A, D215G, 241-243del, K417N, E484K, N501Y, D614G

and A701V), Delta (T19R, 156-157del, R158G, L452R, T478K, D614G, P681R and D950N),

235 Omicron BA.1 (A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D,

236 S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,

237 Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K,

238 Q954H, N969K, L981F) and Omicron BA.4/5 (T19I, L24S, 25-27del, 69-70del, G142D, V213G,

239 G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N,

240 T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K,

241 D796Y, Q954H, N969K). Pseudoviruses were produced by co-transfection in 293T/17 cells

with a lentiviral backbone (HIV-1 pNL4.luc encoding the firefly luciferase gene) and either of

the SARS-CoV-2 spike plasmids with PEIMAX (Polysciences). Culture supernatants were

244 clarified of cells by a 0.45 μM filter and stored at -70°C. Plasma samples were heat-inactivated

and clarified by centrifugation. Pseudovirus and serially diluted plasma/sera were incubated

for 1 h at 37°C. Cells were added at  $1 \times 10^4$  cells per well after 72 h of incubation at 37°C.

Luminescence was measured using PerkinElmer Life Sciences Model Victor X luminometer.
Neutralization was measured as described by a reduction in luciferase gene expression after
single-round infection of 293T/ACE2.MF cells with spike-pseudotyped viruses. Titers were
calculated as the reciprocal plasma dilution (ID<sub>50</sub>) causing 50% reduction of relative light units.

# 252 Antibody-dependent cellular cytotoxicity (ADCC) assay

253 The ability of plasma antibodies to cross-link FcyRIIIa (CD16) and spike expressing cells was 254 measured as a proxy for ADCC as previously described. HEK293T cells were transfected with 5 µg of SARS-CoV-2 wild-type variant spike (D614G), Beta, Delta and Omicron BA.1 spike 255 plasmids using PEI-MAX 40,000 (Polysciences) and incubated for 2 days at 37°C. Expression 256 of spike was confirmed by binding of CR3022 and P2B-2F6 and their detection by anti-IgG 257 APC (Biolegend) measured by flow cytometry. Subsequently, 1x10<sup>5</sup> spike-transfected cells per 258 well were incubated with heat inactivated plasma (1:100 final dilution) or control mAbs (final 259 concentration of 100 µg/mL) in RPMI 1640 media supplemented with 10% FBS and 1% 260 261 Pen/Strep (R10; Gibco) for 1 h at 37°C. Jurkat-Lucia™ NFAT-CD16 cells (Invivogen) (2x10<sup>5</sup> 262 cells/well) were added and incubated for 24 h at 37°C. Twenty µl of supernatant was then transferred to a white 96-well plate with 50 µl of reconstituted QUANTI-Luc secreted luciferase 263 and read immediately on a Victor 3 luminometer with 1s integration time. Cells were gated on 264 265 singlets, live cells (determined by Live/dead™ Viability dye; Thermofisher Scientific), and 266 those cells that were positive for IgG and spike specific monoclonal antibodies binding to their 267 surface. Relative light units (RLU) of a no antibody control were subtracted as background. Palivizumab was used as a negative control, while CR3022 was used as a positive control, 268 and P2B-2F6 to differentiate the Beta from the D614G variant. To induce the transgene, 1x 269 270 cell stimulation cocktail (Thermofisher Scientific) and 2 µg/ml ionomycin in R10 was added as a positive control. 271

272

#### 273 Measurement of antigen-specific T cells by flow cytometry

T-cell responses to SARS-CoV-2 spike or human adenovirus 26 (Ad26) hexon and penton 274 were measured as previously described [3]. Briefly, cryopreserved PBMC were thawed, 275 276 washed and rested in RPMI 1640 (Sigma-Aldrich) containing 10% heat-inactivated FBS (HyClone) for 4 h prior to stimulation. PBMC were seeded in a 96-well V-bottom plate at 277 ~2x10<sup>6</sup> PBMC per well and stimulated with either a commercial ancestral SARS-CoV-2 spike 278 (S) pool (1 µg/mL, Miltenyi Biotec) or a Ad26 peptide pool containing 293 peptides (15mers 279 with 10-aa overlap) spanning the Ad26 hexon and penton proteins (1 µg/mL). All stimulations 280 281 were performed in the presence of Brefeldin A (10 µg/mL, Sigma-Aldrich) and co-stimulatory 282 antibodies against CD28 (clone 28.2) and CD49d (clone L25) (1 µg/mL each, BD Biosciences). As a negative control, PBMC were incubated with co-stimulatory antibodies, 283 Brefeldin A and an equimolar amount of DMSO. After 16 h of stimulation, cells were washed, 284 stained with LIVE/DEAD<sup>™</sup> Fixable Near-IR Stain (Invitrogen) and subsequently surface 285 stained with the following antibodies: CD14 APC-Cy7 (HCD14), CD19 APC-Cy7 (HIB19), CD4 286 BV785 (OKT4), CD8 FITC (RPA-T8), CD45RA BV570 (HI100) (Biolegend) and CD27 PE-Cy5 287 288 (1A4, Beckman Coulter). Cells were then fixed and permeabilized using a Cytofix/Cytoperm 289 buffer (BD Biosciences) and stained with CD3 BV650 (OKT3), IFN-g BV711 (4S.B3), TNF-a PE-Cy7 (Mab11) and IL-2 PE/Dazzle<sup>™</sup> 594 (MQ1-17H12) from Biolegend. Finally, cells were 290 washed and fixed in CellFIX (BD Biosciences). Samples were acquired on a BD Fortessa flow 291 292 cytometer and analyzed using FlowJo (v10.8.1, FlowJo LLC). Results are expressed as the 293 frequency of total memory CD4+ or CD8+ T cells expressing IFN-g, TNF-a or IL-2. Due to high 294 TNF-a backgrounds, cells producing TNF-a alone were excluded from the analysis. All data are presented after background subtraction. 295

296

#### 297 Outcomes

The primary objectives of the study were to evaluate safety and reactogenicity and humoral and cellular immunogenicity to full and half dose homologous and heterologous booster vaccinations, at each study visit. Primary endpoint measures included measuring nucleocapsid binding antibody titers, neutralization titers and T-cell response magnitudes.

302 Safety was measured by participant self-report using diary cards and graded according to FDA standards [49]. The primary immunogenicity endpoint was defined as any study arm 303 304 eliciting <75% of the highest geometric mean titre (GMT) response in the study. Together with 305 the DSMB, the study team used this criteria to determine whether a subsequent booster should be offered to participants, and which booster if so. In this study, based on results, all 306 participants except those who received the full dose BNT162b2 vaccination, were offered a 307 308 full dose BNT162b2 booster in addition to that received according to their original 309 randomisation.

310

## 311 Statistical Analysis

- A two-tailed Wilcoxon signed-rank test or a Friedman test with Dunn's correction was used to
- 313 assess statistical differences between paired samples. A Mann-Whitney test or a Kruskal-

314 Wallis test with Dunn's corrections was used to compare multiple groups. Correlations were

tested by a two-tailed non-parametric Spearman's rank test. In all cases, P values of less than

- or equal to 0.05 were considered significant.
- 317

### 318 Data Sharing

Protocol and data underlying the findings described in this manuscript may be obtained fromthe lead authors upon request.

321

### 322 Study Approval

323 This study has been approved by the South African Health Products Regulatory Authority

324 (SAHPRA, number: 20210423) and all site-specific Human Research Ethics Committees

Wits: 211001B, UKZN: BREC/00003487/2021, UCT: 680/202). All participants provided
written informed consent..

## 327 Results

## 328 Participants and follow up.

- Between December 8, 2021, and July 27, 2022, 333 participants were screened and 289
- randomized to 4 arms: Arm A: Full-dose Ad26.COV2.S (5x10<sup>10</sup> vp/mL, 74 participants); Arm B:
- half-dose Ad26.COV2.S (2.6x10<sup>10</sup> vp/mL, 69 participants); Arm C: Full-dose BNT162b2
- 332 (30mcg, 73 participants); and Arm D: half-dose BNT162b2 (15mcg, 73 participants) (Table 1
- and Figure 1). Participants were followed for 24 weeks, overall retention was 93.1% at 24
- 334 weeks (**Table 1**).
- The majority of participants (53.6%, 155/289) were between 30 and 45 years old, with 36/189
- 336 (12.5%) 55 years and older, and 238/289 (82.4%) female. In the cohort, 116/289 (40.1%)
- 337 were PLWH, 16 (13.8%) were considered viremic (VL >200cps/ml) and had a median CD4
- count of 452 cells/mm<sup>3</sup> (IQR: 132-538), whereas participants who were virologically
- 339 suppressed (VL <200cps/ml) had a median CD4 count of 708 cells/mm<sup>3</sup> (IQR: 558-922). At
- randomisation, subsequently referred to as baseline, 61/289 (21.1%) of participants had
- 341 hypertension, 30/289 (10.4%) anaemia, and 174/289 (60.2%) were obese. Other
- 342 comorbidities were less common (asthma and diabetes mellitus 4.2% each, arthritis 2.4% and
- tuberculosis 2.1% respectively).
- 344 Evidence of previous SARS-CoV-2 infection (positive nucleocapsid antibody detected by
- ELISA) was present in 91.4% (213/223) of participants tested at baseline indicating a high
- 346 degree of hybrid immunity in the trial cohort. This was similar amongst the four vaccination
- arms, namely 91.2% (52/57), 87.9% (51/58), 93.2% (55/59) and 93.2% (55/59) for half-dose
- Ad26.COV2.S, full-dose Ad26.COV2.S, half-dose BNT162b2 and full-dose BNT162b2,
- respectively. These high levels of nucleocapsid positivity were sustained 2, 12 and 24 weeks
- after the booster dose, with greater than 80% nucleocapsid positivity at any given time point.
- Participants received the booster vaccine at a median of 271 days (IQR: 255-296) after the
- 352 Ad26.COV2.S prime. Nine breakthrough infections (BTI) were confirmed by SARS-CoV-2
- 353 PCR during the trial and all were mild infections that resolved within 4-12 days, 7/9 in the

Ad26.COV2.S arms. Three BTI occurred between W2 and W12, and the remainder between
W12 and W24 (median: 17.1 weeks post boost).

356

## 357 Safety and reactogenicity of the booster vaccination regimens

- 358 Reactogenicity was measured through participant-completed diary cards, recording solicited
- 359 local and systemic adverse reactions, as well as unsolicited adverse reactions through day-7
- 360 post booster, or longer if adverse events persisted. Overall, safety profiles were comparable
- 361 between the four trial arms. Localised pain, headache, localised tenderness and weakness
- were reported with highest frequency, mostly of grade 1 and 2 severity. Grade 3 or 4 events
- included localised pain (2.0%), tenderness (1.7%), nausea (0.7%), diarrhoea (1.0%),
- 364 headache (1.7%), weakness (2.8%), myalgia (1.0%), chills (0.7%), cough (0.3%), loss of smell
- 365 (0.3%) and loss of taste (0.3%). Unsolicited AEs were uncommon, occurring in 8.7% of
- 366 participants (**Figure 2**).
- 367 No events of thrombosis with thrombocytopenia syndrome (TTS) were reported;
- thrombocytopenia was reported in three participants, two had thrombocytopaenia at baseline.
- 369 There were 14 serious AEs (SAEs) on study, non-related to study product, and no AEs of
- 370 special interest (AESIs).
- 371

#### 372 Antibody responses after booster vaccination

373 We evaluated spike binding antibody titers at baseline (BL) and week 2 (W2), week 12 (W12) 374 and week 24 (W24) post-boost in the four vaccination arms using a trimeric spike ELISA for ancestral D614G virus. Relatively high spike binding antibody titers were detected in all 375 groups at BL (geometric mean titer (GMT), EC<sub>50</sub>; >1000; Figure 3A). This is consistent with 376 377 our observation that the majority of participants showed evidence of prior infection (Table 1). Spike antibody titers in the half- and full-dose Ad26.COV2.S arms were not significantly 378 boosted by W2 (1.15 and 1.29 fold change in GMT, respectively), and did not change 379 380 significantly up to W24. In contrast, half- and full-dose BNT162b2 arms demonstrated a 381 significant increase in binding antibody titers at W2 (3.9 and 4.54 fold change, respectively), to

a GMT >4500 (Figure 3A). Spike binding antibodies in the BNT162b2 arms reduced to half 382 that of W2 titers by W12, and had returned to BL levels by W24. These kinetics were reflected 383 in a significantly higher fold-change between W2 and BL in the BNT162b2 arms compared to 384 the Ad26.COV2.S arms (Figure 3B). Although waning had occurred by W12, EC<sub>50</sub> titers in the 385 BNT162b2 arms were still significantly higher than the Ad26.COV2.S arms (Figure 3C). While 386 some differences between the arms persisted at W24, relatively high antibody titers, similar to 387 those observed at BL and prior to a boost, were noted in all four arms, with GMT of 1016, 388 389 1140, 1563 and 1686 for half-dose Ad26.COV2.S, full-dose Ad26.COV2.S, half-dose 390 BNT162b2 and full-dose BNT162b2, respectively.

391

392 Using a live virus neutralization assay, we evaluated neutralizing antibody titers to the 393 ancestral D614G virus and Omicron BA.5, which was the most recent dominant sub-lineage at 394 the time of W24 collection. At BL, neutralization activity against the D614G virus was similar between the arms (GMT FRNT<sub>50</sub> values of 546, 345, 393 and 334 for half-dose Ad26.COV2.S, 395 396 full-dose Ad26.COV2.S, half-dose BNT162b2 and full-dose BNT162b2, respectively; Figure 397 **4A**). When measured at W2, half-dose Ad26.COV2.S did not boost BL neutralizing titers, while full-dose Ad26.COV2.S led to a 2.14-fold increase (Figure 4B). Both doses of 398 BNT162b2 demonstrated a superior ability to boost neutralizing antibodies at W2 (8.5 to 10.2-399 400 fold compared to BL), with all but one participant increasing neutralizing titer (Figure 4B). As 401 expected from its known immune evasion properties, FRNT<sub>50</sub> values for BA.5 neutralization were considerably lower than for ancestral virus (GMT of 84, 75, 84 and 63 for the four arms, 402 respectively; Figure 4C). The kinetics mirrored those for D614G neutralization, with both 403 doses of BNT162b2 demonstrating enhanced boosting of neutralizing antibodies compared to 404 405 Ad26.COV2.S (Figure 4D). By week 24, neutralizing titers had waned significantly for the D614G virus, to a GMT of 732 and 840 for the BNT162b2 half- and full-doses, which was 406 significantly higher than full-dose Ad26.COV2.S, with a GMT of 292 (Figure 4E). 407 408 Neutralization of BA.5 was poor at W24 (GMT of 73-192), with no differences between the

groups. Five participants with documented BTI between W2 and W24 (Figure 4A,C, red
lines) showed boosted neutralization activity, as expected.

411

412 In parallel, we assessed neutralizing antibody titers against an expanded panel of virus variants, namely D614G, Beta, Delta, Omicron BA.1 and BA.4/5 (which share identical spikes) 413 using a lentiviral pseudovirus assay, limited to HIV-negative participants in the cohort. The 414 data were consistent with our observations from the live virus assay, where significant 415 416 boosting of neutralizing antibodies occurred at W2 against all variants for BNT162b2, but not for either the half- or full- dose Ad26.COV2.S (Figure 5). Titers against all variants declined 417 from the W2 peak by W12, with a 2.4 to 5.7-fold drop, and levels remained constant to W24, 418 with BNT162b2 arms trending to higher titers, regardless of the variant at W24. 419 420 421 Finally, we investigated antibody-dependent cellular cytotoxicity (ADCC) responses against the D614G, Beta, Delta and BA.1 spikes (Figure 6A and 6B) at BL and 2 weeks post-boost. 422 423 As observed for the binding and neutralizing antibody responses, there was no increase in 424 titers at W2 for either the half- or full-dose Ad26.COV2.S arms (median fold change 0.97 and 0.91, respectively), consistent with the fact that binding antibodies and ADCC potential are 425 generally correlated. However, the half-dose BNT162b2 failed to trigger increased ADCC 426 427 (median change 1.01), in contrast to the binding and neutralization results. For the full-dose 428 BNT162b2 we observed marginally but nevertheless significantly higher ADCC titers against

D614G, Beta and BA.1 spike at W2 compared to BL, but not to the same extent as binding orneutralizing responses.

431

### 432 **T-cell responses before and after booster vaccination**

433 We also measured SARS-CoV-2 spike-specific T-cell responses before and after homologous

and heterologous vaccination with full or half-dose vaccines (n=214). Prior to boosting, spike-

specific CD4+ responses were detected in most participants (>94.4%), with a frequency

436 comparable between the four arms (Figure 7A). Two weeks after booster immunization, the

frequency of spike-specific CD4+ T cells was significantly increased in participants who 437 received BNT162b2 compared to BL (median: 0.23% vs 0.12% for half dose BNT162b2 and 438 439 0.25% vs 0.11% for full dose BNT162b2, respectively), while in participants boosted with Ad26.COV2.S, the median frequency of SARS-CoV-2 spike-specific CD4+ T cells, while 440 statistically higher than BL, demonstrated only a marginal increase (0.12% vs 0.10% for half 441 dose and 0.15% vs 0.11% for full dose) (Figure 7B). The median fold change in CD4+ 442 response between BL and W2 was significantly greater after a BNT162b2 booster (1.8 for half 443 444 dose and 1.98 for full dose) compared to an Ad26.COV2.S booster (1.1 for both half and full dose; Figure 7C). Overall, ~80% of participants boosted with BNT162b2 (regardless of the 445 dose) had an increased spike-specific CD4+ T-cell response, while only 35.3% of participants 446 who received half dose Ad26.COV2.S and 43.4% in those receiving a full dose Ad26.COV2.S 447 booster expanded their CD4+ T-cell responses (Figure 7D). Spike-specific CD8+ T-cell 448 responses were less frequent than CD4+ responses, detected in only ~55% of the participants 449 450 at BL, and for those with a CD8+ response, the frequency of spike-specific CD8+ T cells was 451 comparable between the four groups at BL (Figure 7E). Two weeks after boosting, a 452 significant increase in the median CD8+ T-cell response was observed after a full-dose of Ad26.COV2.S (p = 0.002) and both half- or full-dose of BNT162b2 (p = 0.003 and p < 0.001. 453 respectively; Figure 7F). Assessing only participants with a spike CD8+ response at both time 454 455 points, the median fold change at W2 post-boost was significantly higher after a BNT162b2 456 booster (1.91 for half-dose and 2.24 for full-dose) compared to an Ad26.COV2.S booster (1.22 457 for half-dose and 1.24 for full-dose; Figure 7G). However, it is important to note that individual responses were highly variable within all groups, with spike-specific CD8+ responses 458 contracting, remaining negative or expanding. Overall, approximately half of participants 459 460 boosted with BNT162b2 displayed an increase in spike-specific CD8+ T-cell responses, whereas an expansion of the CD8+ response was observed in only 1/3 of participants who 461 received a half-dose Ad26.COV2.S booster and ~40% in those receiving a full-dose 462 463 Ad26.COV2.S booster (Figure 7H).

464

465 The durability of T-cell responses was then assessed by measuring spike-specific T cells 24 466 weeks after the booster vaccination in a subset of participants (n=190). Pairwise comparison of spike-specific CD4+ T-cell frequencies at W24 relative to W2 demonstrated a significant 467 468 contraction in the CD4+ response for all groups (p <0.001 for both BNT162b2 boosters and half-dose Ad26.COV2.S and p = 0.0047 for full-dose Ad26.COV2.S), subsiding to BL levels 469 (Figure 8A). Consequently, 24 weeks post-boosting, the magnitude of spike-specific CD4+ T 470 cells was comparable in all trial arms (Figure 8B). In contrast, the median frequency of spike-471 472 specific CD8+ T cells appeared to increase between W2 and W24 in the Ad26.COV2.S group, although individual responses were highly variable, with some participants showing 473 474 substantial waning or stable levels while others demonstrated gain of a CD8+ T-cell response that could be related to an undocumented BTI (Figure 8C). Overall, as for the CD4+ T-cell 475 476 response, the frequency of spike-specific CD8+ T cells was similar across the four vaccine 477 regimens when examined 24 weeks after booster vaccination (Figure 8D).

478

### 479 **PLWH develop comparable antibody and T-cell responses after boosting**

480 To determine whether HIV infection impacts vaccine booster responsiveness, participants were stratified by their HIV status. Prior to boosting, significantly lower titers of both binding 481 and live virus neutralizing antibodies were found in PLWH who were viremic (viral load >200 482 483 HIV-1 mRNA copies/mL, n = 10) compared to virally suppressed individuals, who had similar 484 antibody profiles to HIV-negative individuals (Figure 9A-B). Examination of baseline T-cell 485 responses also revealed deficiencies, where significantly fewer viremic PLWH displayed spike-specific T-cell responses compared to aviremic and HIV-negative participants at BL 486 (50% vs 100% and 97.6% for CD4+ and 10% vs 58.2% and 57.6% for CD8+; Figure 9C-D). 487 488 Two weeks after booster vaccination, there was no difference in the degree of boosting (as measured by median fold-change between W2 and BL) for binding or neutralizing antibody 489 titers between PLWH and HIV-negative participants for all vaccination groups (Figure 9E-F). 490 491 For T-cell responses, however, the median fold change in CD4+ response in the full dose 492 BNT162b2 group was significantly lower in PLWH compared to the HIV-negative participants

493 (1.52 vs 2.21, respectively, p = 0.037), with a trend towards lower fold-change in CD8+ spike 494 T-cell responses in PLWH (p = 0.065; **Figure 9G-H**). Of note, a high proportion of viremic 495 participants did not mount any CD4+ (4/10) or CD8+ T-cell responses (4/10) after any of the 496 vaccine boosts, indicative of the impact of immunosuppression (**Supplementary Fig S1**). 497

At W24, comparable titers of binding and neutralizing antibodies were detected between 498 PLWH and HIV-negative participants in all vaccination groups, and T-cell frequencies did not 499 500 show any deficiencies in PLWH (Figure 9I-L). In fact, significantly higher frequencies of spikespecific CD4+ T cells were observed in PLWH in some vaccination groups (Figure 9K), 501 possibly reflecting persistence of the higher baseline CD4+ T-cell responses observed in 502 PLWH. Overall, these data suggest that some differences in the degree of boosting in PLWH, 503 504 but by 24 weeks after revaccination, the frequencies of binding and neutralizing antibodies as 505 well as spike-specific CD4+ and CD8+ T cells were comparable between HIV-negative participants and PLWH. This suggests that SARS-CoV-2 specific responses persist to a 506 507 similar extent in those with well-controlled HIV infection compared to HIV-negative individuals. 508 A proportion of viremic individuals, however, may be at risk of impaired T-cell responses and 509 less durable antibody responses over the long term.

510

## 511 Anti-vector immunity is detectable but may not account for the limited ability of

### 512 Ad26.COV2.S to boost spike-specific responses

513 We hypothesized that the muted capacity of Ad26.COV2.S to boost spike responses,

514 compared to BNT162b2, may be due to anti-vector immunity, given that prior studies

515 demonstrated that pre-existing Ad5 vector-specific nAbs and T cells have the capacity to limit

- responses to the transgene immunogen [44-46]. To measure anti-Ad26 neutralizing antibody
- 517 activity, we established an Ad26 neutralization assay in which dilutions of plasma from
- vaccinees were mixed with the Ad26.COV2.S vaccine, and vector infection was measured by
- spike expression in the Ad26 vector infected cells (**Figure 10A-B**). To quantify Ad26-specific
- 520 neutralizing activity before and after boosting, we titrated participant plasma to obtain the

521 plasma concentration needed to inhibit 50% of cellular infections with the Ad26 vector 522 represented as  $ID_{50}$ , the reciprocal of this plasma dilution (**Figure 10C**). We tested 24 participants who had received full dose Ad26.COV2.S, and compared them to 24 participants 523 524 who were boosted with BNT162b2, where no expansion of the vector-specific response would be expected. At BL, the majority of participants in both groups had Ad26-specific neutralizing 525 antibody responses above the level of quantification (Figure 10D). Two weeks later, there was 526 a significant increase in vector-specific ID<sub>50</sub> in the Ad26.COV2.S boosted group (p = 0.0006), 527 528 but no boosting in the group receiving BNT162b2 (median fold-change in nAb ID<sub>50</sub> between W2 and BL: 1.83 for Ad26.COV2.S and 0.87 for BNT162b2; Figure 10E). To determine the 529 level of neutralizing immunity against Ad26.COV2.S before primary Ad26.COV2.S vaccination, 530 531 we investigated an independent cohort where participants were vaccinated with Ad26.COV2.S 532 for the first time, with a subset accessing a second Ad26.COV2.S vaccine (Supplementary Table 1). The levels of anti-Ad26 neutralizing immunity prior to Ad26.COV2.S prime 533 vaccination were below the level of quantification in all but one participant. Titers were 534 535 significantly higher after an Ad26.COV2.S prime (p < 0.0001; Figure 10F) but did not further 536 increase after a boost, and were of similar magnitude to those in the BaSiS trial (Figure 10F). Finally, we investigated the association between Ad26-specific nAb titer at BL and the fold-537 change in spike neutralizing titer from W2 to BL, but found no correlation (Figure 10G). 538

539

540 To measure Ad26-specific T-cell responses, we stimulated PBMC with a pool of peptides 541 spanning the viral hexon and penton proteins of Ad26 and characterized T-cell cytokine responses by flow cytometry. Ad26-specific T cells were readily detectable at BL and 2 weeks 542 543 post-boosting (Figure 11A). We tested 44 participants who had received full-dose 544 Ad26.COV2.S, and compared them to 20 participants who were boosted with BNT162b2, as a control group. At baseline, all participants in both groups had a CD4+ T-cell response to Ad26 545 (Figure 11B). Two weeks after Ad26.COV2.S booster vaccination, there was no overall 546 547 increase in the Ad26-specific CD4+ response, which resembled the group who received the 548 BNT162b2 booster. When comparing the fold-difference in the response from BL to W2, there

was a minor increase in the Ad26.COV2.S-boosted group (1.08 for Ad26.COV2.S and 0.91 for 549 550 BNT162b2), reflecting a proportion of participants who had a marginal increase in the 551 frequency of Ad26-specific CD4+ T cells (Figure 11C). We also investigated an independent 552 unvaccinated healthcare worker cohort prior to Ad26.COV2.S vaccination (Supplementary Table 2); cross-sectional analysis indicated a significant, 3-fold higher magnitude of Ad26-553 specific CD4+ T-cell responses 4 weeks after vaccination (p = 0.017; Figure 11D), similar to 554 what we observed for Ad26 nAb responses. Interestingly, 85% of participants had an existing 555 556 adenovirus CD4+ response even before the priming dose, which is the likely result of conserved T-cell cross-reactivity due to infection with other adenoviral types. 557 Similarly, we characterized CD8+ T-cell responses specific for Ad26. These were detectable 558 in 75% of participants at baseline, and unlike CD4+ responses, were boosted significantly (p =559 0.002) by a second dose of Ad26.COV2.S, demonstrating an increase in response of 1.2 560 compared to 0.95 for the BNT162b2-boosted group (Figure 11E and F). CD8+ responses 561 were more rare in the cohort not previously vaccinated with Ad26.COV2.S, detectable in only 562 563 35% of unvaccinated participants. These were significantly higher (p = 0.005) and detectable 564 in 81.8% of individuals 4 weeks after initial Ad26.COV2.S vaccination, at a magnitude and range similar to the baseline responses in our trial (Figure 11G). Importantly, and consistent 565 with Ad26-specific nAb responses, there was no association between the magnitude of Ad26-566 567 specific CD4+ or CD8+ T cells and spike-specific T-cell responses, either at BL or W2 (Figure 568 **11H**). Overall, anti-vector humoral and cellular immunity was abundantly detectable in our trial 569 participants, but neither appeared to have a clear effect on dampening spike-specific 570 responses.

#### 571 Discussion

572 In this trial we evaluated the safety and immunogenicity of fractional and full doses of the Janssen adeno-vectored Ad26.COV2.S vaccine and the Pfizer BNT162b2 mRNA vaccine in 573 574 an open label phase 2 trial of adults who had previously received a single dose of Ad26.COV2.S. The overwhelming majority of participants had detectable anti-nucleocapsid 575 responses prior to receiving their boosts, indicating prior SARS-CoV-2 infection and boosting 576 on the background of extensive hybrid immunity. We investigated safety and immunogenicity 577 578 in both HIV-negative participants and PLWH, with the latter group generally well-controlled with VL suppression, and only 13.8% of PLWH being viremic (VL >200 cps/ml). Safety profiles 579 in all four booster regimens were similar, with no regimen resulting in appreciable increased 580 reactogenicity beyond localized responses at the injection site and mild, transient symptoms 581 582 such as headache and weakness. Documented BTI, while few, mostly occurred in the 583 Ad26.COV2.S boosted participants.

Heterologous boosting with the BNT162b2 mRNA vaccine was superior to homologous 584 585 vaccination at early time points (2-12 weeks) by multiple humoral and cellular immune 586 measures, including binding and neutralizing antibodies, and CD4+ T-cell responses to SARS-CoV-2 spike. This result is consistent with other studies showing better neutralizing antibody 587 and T-cell responses after heterologous relative to homologous boosting of Ad26.COV2.S 588 589 with an mRNA vaccine [23, 50]. Similar results were observed with mRNA vaccine 590 heterologous boosting of the ChAdOx1 chimpanzee adeno-vectored vaccine [51, 52]. 591 In contrast to the BNT162b2 vaccine, a homologous Ad26.COV2.S boost elicited limited, if any boosting of immune responses. Binding antibodies, neutralization, and T-cell responses 592 increased 2-fold or less, and halving the dose resulted in no detectable booster activity. In 593 594 contrast, boosting with BNT162b2 gave a 4- to 10-fold increase of antibody responses, with the exception of ADCC (discussed below), and 80% of trial participants had increased spike 595 specific CD4+ T-cell responses. Unlike with Ad26.COV2.S, halving the dose of BNT162b2 did 596 597 not strongly decrease the response to the booster in terms of either elicited binding 598 antibodies, neutralizing antibodies, or CD4+ T-cell responses. Despite the strong boosting

effect of BNT162b2, waning of the binding and neutralizing antibody responses was 599 pronounced by 12 weeks post-boost and by week 24, titers had declined close to the relatively 600 601 high baseline titers. For ADCC, which generally correlates well with binding and neutralization, the absence of boosting by Ad26.COV2.S is expected, given the lack of boosting overall. 602 However the marginal ADCC boosting observed only in the full-dose BNT162b2 arms (despite 603 increased binding and neutralization) may be a consequence of class switching towards the 604 IgG4 subclasses, which does not effectively mediate ADCC, as recently reported for repeated 605 606 mRNA vaccination [53, 54].

The effects of HIV status on the neutralizing antibody and T-cell responses were moderate, 607 and largely limited to reduced responses observed at baseline in PLWH with HIV viremia 608 609 (despite the small size of this group). Both binding neutralizing antibody responses to ancestral SARS-CoV-2 were significantly lower in HIV viremic participants at baseline, while 610 611 there was no difference between aviremic PLWH and HIV-negative participants. CD4+ T-cell responses showed a more marked difference with only 50% of viremic PLWH having 612 613 detectable spike-specific CD4+ T cells, compared with 100% of aviremic PLWH and 97% of 614 HIV-negative participants. For CD8+ T cells, the fraction of detectable spike-specific cells was 58% for both aviremic PLWH and HIV negative participants. In contrast, only 1 out of 10 HIV 615 viremic participants had a detectable spike-specific CD8+ T-cell response. Interestingly, the 616 617 median fraction of spike specific CD4+ T cells was significantly higher in aviremic PLWH than 618 the HIV-uninfected participants, perhaps indicative of a different SARS-CoV-2 course of 619 infection in PLWH [27] or interactions of SARS-CoV-2 immunity with HIV-mediated partial immune activation in HIV suppressed PLWH [55]. 620

Post-boost, binding antibodies and neutralization were generally similar between PLWH and HIV negative participants. Even viremic PLWH showed increased binding and neutralizing antibody responses after BNT162b2 vaccination, and these were within the range seen in the other participants. These results are consistent with previous studies that PLWH have good antibody responses to vaccination [19, 38, 39, 56] with the exception of those with CD4+ T cell concentrations than 200 cells/mm<sup>3</sup> [34, 36, 37, 57, 58]. T-cell responses were more strongly

affected by HIV status: they were significantly lower for spike-specific CD4+ T cells in PLWH 627 boosted with a full-dose of BNT162b2. We did not detect an increase in spike-specific CD8+ 628 629 T-cell responses with full-dose BNT162b2, although the results did not reach statistical significance. The interpretation of the CD4+ T cell results is complicated by the higher median 630 absolute fraction of spike-specific CD4+ T cells in PLWH post- BNT162b2 boost. 631 Although the Ad26.COV2.S is known to trigger lower responses than BNT162b2, the almost 632 complete absence of boosting by this vaccine in our cohort was striking. We thus assessed 633 634 whether this was caused by anti-vector immunity. Vaccination with adenovirus 5 vectored vaccines elicits both neutralizing antibody and T-cell immunity to the vector itself, decreasing 635 the efficiency of cellular infection with the vaccine vector and attenuating the vaccine response 636 [44-46]. Using the samples from this trial and supplementing with other cohorts where a pre-637 638 Ad26.COV2.S prime vaccination sample was available, we observed negligible Ad26.COV2.S neutralizing activity in vaccine-naïve donors. However, a single dose of Ad26.COV2.S strongly 639 increases both neutralizing titers against Ad26.COV2.S and the fraction of Ad26-specific 640 641 CD4+ and CD8+ T cells. Nevertheless, as with other studies of anti-Ad26.COV2.S 642 neutralization, we could not find a clear association between the levels of anti-vector immunity, either neutralizing or T cell, and the degree of immune response post-Ad26.COV2.S boost, as 643 previously reported [47, 48]. 644 To conclude, we show that in the context of high levels of hybrid immunity, heterologous 645

boosting with the BNT162b2 mRNA vaccine following a Ad26.COV2.S prime demonstrated

647 superior immunogenicity and was safe and effective in both PLWH and HIV-negative

648 participants, although there was a rapid waning of binding and neutralizing antibody

responses. The Ad26.COV2.S homologous boost was also safe but showed highly attenuated

650 immunogenicity relative to BNT162b2, both in antibody and T-cell immunity. While the

Ad26.COV2.S vaccine elicited strong anti-vector immunity, we did not find clear evidence that

652 this was the cause of attenuation.

## 653 Author contributions

Study design: LF, ASi, PLM, WAB, GG, L-GB, HR, SS, EL in collaboration with the sponsor 654 (SAMRC). Data curation: JNB, TM-G, SS, NG, NN, EL. Experiment/investigation: RSK, RN, 655 656 MAO, HM, RB, ANg, AW, SG, AAN, SFJM, ASB, NB, PM, SC, YG, KK, TM-G, ZM, EV, SvG, PK, QM, FA, SRB, TPM, TH, NPM, NBM, HK, MM, FP, JLR, SS, NG, NN, EL, RP, ANa. 657 Methodology: WAB, CR, ASi, PLM, JNB, SIR, FP, SS. Data Analysis: WAB, CR, MPB, GL, 658 ASi, PLM, JNB, SIR, LF, JLR, SS. Resource: AG, ASe. Project administration: WAB, ASi, 659 660 PLM, JNB, CC, LF, FP, JLR, SS, NG, NN, TPN, MD, KMG. Writing (original draft): LF, PLM, ASi, WAB, CR, JNB, SS. Writing (review and editing): All authors reviewed and approved the 661 final draft. 662

663

## 664 Acknowledgements and funding

We thank all the trial participants who contributed to this study. This study was funded by the 665 South African Medical research Council (SAMRC), the Bill and Melinda Gates Foundation, 666 667 through the Global Immunology and Immune Sequencing for Epidemic Response (GIISER) 668 program (INV-030570) and the Wellcome Trust (226137/Z/22/Z). P.L.M is supported by the SAMRC (96833) and is an Department of Science and Innovation-National Research 669 Foundation South African Research Chair (98341). A.Si. is supported by the Bill and Melinda 670 Gates foundation (INV-046743) and the SAMRC (D2112300-01). W.A.B. is supported by the 671 672 EDCTP2 program of the European Union's Horizon 2020 programme (TMA2016SF-1535-673 CaTCH-22) and the EU-Africa Concerted Action on SARS-CoV-2 Virus Variant and Immunological Surveillance (COVICIS), funded through the EU's Horizon Europe Research 674 and Innovation Programme (101046041). C.R. is supported by the EDCTP2 program 675 676 (TMA2017SF-1951-TB-SPEC). This project has also been funded in part by the National Institute of Allergy and Infectious Diseases, NIH, Department of Health and Human Services, 677 under Contract No. 75N93021C00016 to A.G. and 75N93019C00065 to A.Se. The Wits RHI 678 679 site received grant funding from Janssen to conduct the following clinical trials: Ensemble 680 study (3UM1 Al068614-14SI), the Sisonke 1 study (96833), the Sherpa Study (96867) as well

- as Pfizer for the Pfizer C4591015 study (C4591015), Horizon 1 (VAC31518COV2004) and
- Horizon 2 (VAC31518COV3006). For the purposes of open access, the authors have applied
- a CC-BY public copyright license to any author-accepted version.
- 684

## 685 **Declaration of interest:**

- 686 A.Se. is a consultant for AstraZeneca Pharmaceuticals, Calyptus Pharmaceuticals, Inc,
- 687 Darwin Health, EmerVax, EUROIMMUN, F. Hoffman-La Roche Ltd, Fortress Biotech, Gilead
- 688 Sciences, Granite bio., Gritstone Oncology, Guggenheim Securities, Moderna, Pfizer,
- 689 RiverVest Venture Partners, and Turnstone Biologics. A.G. is a consultant for Pfizer. LJI has
- 690 filed for patent protection for various aspects of T cell epitope and vaccine design work. All
- 691 other authors declare no competing interests.

#### 692 Figure legends

693

Figure 1: Study design and CONSORT diagram. (A) Study design. (B) CONSORT flow
diagram. BL: baseline, nAbs (Live): Live virus neutralization assay; nAbs (Pseudo):
pseudovirus neutralization assay. Binding Abs: Spike-specific IgG ELISA. ADCC: Antibodydependent cellular cytotoxicity assay. T-cell response: Spike-specific T-cell intracellular
cytokine staining assay.

699

Figure 2: Recorded adverse events in each study arm. Distribution of participants
 experiencing adverse events (pain, headache, tenderness, weakness, nausea, diarrhea,
 cough, myalgia, swelling, chills, loss of taste, redness, loss of smell or fever) recorded 1 week

703 post booster vaccination in each study arm.

704

Figure 3: Spike-specific IgG responses over time in the immunogenicity sub-study 705 706 population. (A) Longitudinal spike-specific IgG titer (EC<sub>50</sub>) at baseline (BL), W2, W12 and 707 W24 after vaccine booster. The color-coded dots and bold lines represent the geometric mean titer (GMT) at each time point. Recorded BTI between W2 and W24 are depicted with a red 708 line. Fold-change in the GMT is indicated at the bottom of each graph. Statistical comparisons 709 710 were performed using a Friedman test with Dunn's correction. (B) Fold change in spike-711 specific IgG titer between W2 and BL in each study arm. Bars represent median fold change. 712 Statistical comparisons were performed using a Kruskal-Wallis test with Dunn's correction. (C) Comparison of spike-specific IgG titer between study arms at W12 (left panel) and W24 (right 713 panel). Bars represent GMT. Statistical comparisons (in B and C) were performed using a 714 715 Kruskal-Wallis test with Dunn's correction.

716

Figure 4: Live-virus neutralization activity against ancestral D614G and BA.5 SARS CoV-2 variant after booster vaccination. Neutralizing titer (FRNT<sub>50</sub>) against ancestral
 D614G (A&B) and Omicron BA.5 (C&D) at BL and post-vaccine booster. A&C show titer at

BL, W2 and W24 post-boost for D614G (A) and BA.5 (C). Fold-change of the GMT is 720 indicated at the bottom of each graph. The color-coded dots and bold lines represent the GMT 721 722 at each time point. Recorded BTI between W2 and W24 are depicted with red lines. Statistical 723 comparisons were performed using a Friedman test with Dunn's correction. B&D show foldchange in neutralizing titer against D614G (B) and BA.5 (D) between BL and W2 in each 724 study arm. Bars represent median fold-change. A Kruskal-Wallis test with Dunn's correction 725 was used to compare different arm groups. (E) Comparison of the neutralizing titer (FRNT<sub>50</sub>) 726 727 against D614G (left panel) and BA.5 (right panel) between study arms at W24. Bars represent 728 GMT. Statistical comparisons were performed using a Kruskal-Wallis test with Dunn's correction. 729 730

Figure 5: Pseudovirus neutralization activity against ancestral D614G, Beta, Delta, BA.1
and BA.4/5 SARS-CoV-2 variants after booster vaccination. Longitudinal neutralizing titer
(ID<sub>50</sub>) against ancestral D614G, Beta, Delta, Omicron BA.1 and BA.4/5 at BL, W2, W12 and
W24 after vaccine booster. Bars represent medians. Bars represent GMT. Statistical
comparisons were performed using a Kruskal-Wallis test with Dunn's corrections. Only HIVnegative participants were included in these analyses.

737

Figure 6: Antibody-dependent cellular cytotoxicity (ADCC) against ancestral (D614G),
Beta, Delta and Omicron BA.1 SARS-CoV-2 variants. (A) ADCC (CD16 signalling) at BL
and W2 in each study arm. Bars represent medians. The grey shaded area indicates an
undetectable ADCC response. Statistical comparisons were performed using a Wilcoxon
matched-pairs signed rank test. (B) Fold change in ADCC activity between W2 and BL in each
study arm. Bars represent median fold change. Statistical comparisons were performed using
a Kruskal-Wallis test with Dunn's corrections.

745

Figure 7: SARS-CoV-2 spike-specific T-cell responses before and 2 weeks after vaccine
 boosting. (A) Comparison of the frequency of spike-specific CD4+ T cells pre-boost in the

four study arms. The grey shaded area indicates undetectable response. (B) Frequency of 748 spike-specific CD4+ T cells before (BL) and after vaccine boost (W2). (C) Fold change in the 749 750 frequency of spike-specific CD4+ T cells between W2 and BL. (D) Overall profile of the 751 evolution of the spike-specific CD4+ T-cell response between BL and W2. (E) Comparison of the frequency of spike-specific CD8+ T cells pre-boost in the four trial arms. (F) Frequency of 752 spike-specific CD8+ T cells before (BL) and after vaccine boost (W2). (G) Fold change in the 753 frequency of spike-specific CD8+ T cells between W2 and BL. (H) Overall profile of the 754 755 evolution of the spike-specific CD8+ T-cell response between BL and W2. Bars represent medians. A two-tailed Wilcoxon signed-rank test was used to assess statistical differences 756 between paired samples and a Kruskal-Wallis with Dunn's corrections was used to compare 757 758 different groups.

759

Figure 8: Kinetics of SARS-CoV-2 spike-specific T-cell response after vaccination. (A) 760 Longitudinal frequencies of spike-specific CD4+ T-cell responses induced by the four different 761 762 booster vaccine regimens. (B) Comparison of the frequency of spike-specific CD4+ T cells 763 between the four arms at W24 post-boost. (C) Longitudinal spike-specific CD8+ T-cell responses induced by the four booster vaccine regimens. (D) Comparison of the frequency of 764 spike-specific CD8+ T cells between the four arms at W24 post-boost. The proportion of spike 765 766 CD8+ responders is indicated at the top of the graph. The grey shaded area indicates 767 undetectable response. The color-coded dots and bold lines in (A) and (C) represent the 768 median at each time point. Recorded BTI between W2 and W24 are depicted with a red line. A Friedman test with Dunn's correction was used to assess statistical differences between 769 paired samples and a Kruskal-Wallis with Dunn's corrections was used to compare different 770 771 groups.

772

Figure 9: Humoral and cellular responses in study participants stratified by HIV status.
 (A to D) Spike-specific binding antibodies (A), live neutralization activity (B), spike-specific
 CD4+ response (C) and spike-specific CD8+ response (D) against ancestral (D614G) SARS-

CoV-2 in HIV-negative (HIV-), PLWH with a viral load <200 HIV mRNA copies/ml (HIV+ Avir) 776 and PLWH with a viral load >200 HIV mRNA copies/ml (HIV+ Vir) before vaccine booster (BL). 777 778 Bars represent GMT for A, B, I, J and medians for all other graphs. Statistical comparisons were performed using a Kruskal-Wallis test with Dunn's corrections. The proportion of T-cell 779 responders is indicated on top of the graph. (E to H) Fold change in spike-specific binding 780 antibodies (E), live neutralization activity (F), spike-specific CD4+ response (G) and spike-781 specific CD8+ response (H) between W2 and BL in each study arm, stratified by HIV status. (I 782 783 to L) Spike-specific binding antibodies (I), live neutralization activity (J), spike-specific CD4+ 784 response (K) and spike-specific CD8+ response (L) against ancestral (D614G) SARS-CoV-2 at W24 after vaccine booster. Viremic PLWH are identified with a cross. Bars represent 785 786 medians. Statistical comparisons between PLWH and HIV-negative groups were performed 787 using a Mann-Whitney test.

788

Figure 10: Ad26-specific neutralizing activity. (A) Schematic representation of the Ad26-789 790 specific neutralization assay. (B) Representative example of spike expression in 791 Ad26.COV2.S-infected H1299 cells measured by flow cytometry. (C) Representative example of the inhibition of spike expression on Ad26.COV2.S-infected H1299 cells when 792 Ad26.COV2.S was pre-incubated with plasma (serial dilution) from a participant vaccinated 793 794 with one full dose of Ad26.COV2.S. (D) Ad26 neutralization activity ( $IC_{50}$ ) pre- and W2 post full 795 dose-Ad26.COV2.S or a full-dose BNT162b2 booster. Statistical difference were assessed 796 using a Wilcoxon matched paired signed rank test. (E) Fold change in Ad26 neutralization activity between W2 and BL in Ad26.COV2.S or BNT162b2 boosted participants. Bars 797 represent GMT for D and F and medians for E. Statistical differences were assessed using a 798 799 Wilcoxon matched paired signed rank test. (F) Comparison of Ad26 neutralization activity  $(IC_{50})$  in individuals who were vaccine naïve (n=14), received one full dose of Ad26.COV2.S 800 (n=14) or received two full doses of Ad26.COV2.S (n=6) from an independent cohort. 801 802 Statistical differences were assessed using a Kruskal-Wallis test with Dunn's correction. (G) 803 Relationship between the fold change in neutralizing titer against D614G SARS-CoV-2

between W2 and BL and Ad26 neutralization activity at BL. Correlation was tested by a twotailed non-parametric Spearman's rank test.

806

Figure 11: Ad26-specific T-cell responses. (A) Representative example of IFN-g production 807 in response to Ad26-specific peptide pool (hexon and penton) in one participant before 808 (baseline) and 2 weeks after a full dose-Ad26.COV2.S booster. (B & E) Frequency of Ad26-809 specific CD4+ T cell (B) and CD8+ T cells (E) pre- and post a full dose-Ad26.COV2.S or a full-810 811 dose BNT162b2 booster. Statistical difference were assessed using a Wilcoxon matched 812 paired signed rank test. (C & F) Fold change in the frequency of Ad26-specific CD4+ T cells (C) and CD8+ T cells (F) between W2 and BL in full-dose Ad26.COV2.S or full-dose 813 BNT162b2 boosted participants. (D & G) Comparison of the frequency of Ad26-specific CD4+ 814 T cells (D) and CD8+ T cells (G) in individuals who are vaccine naïve (n=20) or received one 815 full dose of Ad26.COV2.S (n=11) from an independent cohort. The proportion of Ad26 T- cell 816 responders is indicated at the top of each graph. Statistical differences were assessed using a 817 818 Kruskal-Wallis test with Dunn's correction and a Chi-test to compare proportions. Bars 819 represent medians. (H) Relationship between the frequency of spike-specific T-cell response at BL or W2 and the frequency of Ad26-specific T-cell responses at BL. Correlations were 820 tested by a two-tailed non-parametric Spearman's rank test. 821

medRxiv preprint doi: https://doi.org/10.1101/2023.11.20.23298785; this version posted November 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

#### 822 References

- Bekker LG, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al. Effectiveness of 824 1. the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): 825 826 results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022;399(10330):1141-53. doi: 10.1016/S0140-6736(22)00007-1. PubMed PMID: 827 828 35305740; PubMed Central PMCID: PMCPMC8930006.
- Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the 2. 829 ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 830 2021;384(20):1885-98. Epub 20210316. doi: 10.1056/NEJMoa2102214. PubMed PMID: 831 832 33725432; PubMed Central PMCID: PMCPMC7993410.
- 3. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, et al. T cell responses 833 834 to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022;603(7901):488-92. Epub 20220131. doi: 10.1038/s41586-022-04460-3. PubMed PMID: 35102311; PubMed 835 836 Central PMCID: PMCPMC8930768.
- Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron 4. 837 838 extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 839 2022;602(7898):654-6. Epub 20211223. doi: 10.1038/s41586-021-04387-1. PubMed PMID: 35016196; PubMed Central PMCID: PMCPMC8866126. 840
- 5. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen B, et al. 841 SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. 842 Nat Med. 2021;27(4):622-5. Epub 20210302. doi: 10.1038/s41591-021-01285-x. PubMed 843 844 PMID: 33654292.
- Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 845 6. 501Y.V2 from neutralization by convalescent plasma. Nature. 2021;593(7857):142-6. 846 Epub 20210329. doi: 10.1038/s41586-021-03471-w. PubMed PMID: 33780970; PubMed 847 Central PMCID: PMCPMC9867906. 848
- 7. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 849 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 850 2022;386(16):1532-46. Epub 20220302. doi: 10.1056/NEJMoa2119451. PubMed PMID: 851 852 35249272; PubMed Central PMCID: PMCPMC8908811.
- Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 853 8. Vaccine against Omicron Variant in South Africa. N Engl J Med. 2022;386(5):494-6. Epub 854 855 20211229. doi: 10.1056/NEJMc2119270. PubMed PMID: 34965358; PubMed Central PMCID: PMCPMC8757569. 856
- 9. Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C, et al. SARS-CoV-2 857 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. 858 859 Cell. 2022;185(3):467-84 e15. Epub 20220104. doi: 10.1016/j.cell.2021.12.046. PubMed 860 PMID: 35081335; PubMed Central PMCID: PMCPMC8723827.
- 10. Rossler A. Riepler L. Bante D. von Laer D. Kimpel J. SARS-CoV-2 Omicron Variant 861 Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med. 862 2022;386(7):698-700. Epub 20220112. doi: 10.1056/NEJMc2119236. PubMed PMID: 863 35021005; PubMed Central PMCID: PMCPMC8781314. 864
- 865 11. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Limited 866 neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. EBioMedicine. 2022;82:104158. Epub 867 868 20220711. doi: 10.1016/j.ebiom.2022.104158. PubMed PMID: 35834885; PubMed Central PMCID: PMCPMC9271884. 869
- 12. Cheng SMS, Mok CKP, Leung YWY, Ng SS, Chan KCK, Ko FW, et al. Neutralizing 870 antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and 871 heterologous CoronaVac or BNT162b2 vaccination. Nat Med. 2022;28(3):486-9. Epub 872 20220120. doi: 10.1038/s41591-022-01704-7. PubMed PMID: 35051989; PubMed 873 874 Central PMCID: PMCPMC8940714.
- 13. Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, et al. Antibody evasion by SARS-CoV-875 876 2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608(7923):603-8. Epub

- 877 20220705. doi: 10.1038/s41586-022-05053-w. PubMed PMID: 35790190; PubMed 878 Central PMCID: PMCPMC9385487.
- 14. McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine 879 effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-880 19 in Hong Kong: a population-based observational study. Lancet Infect Dis. 881 2022;22(10):1435-43. Epub 20220715. doi: 10.1016/S1473-3099(22)00345-0. PubMed 882 883 PMID: 35850128; PubMed Central PMCID: PMCPMC9286709.
- 15. Bowen JE, Addetia A, Dang HV, Stewart C, Brown JT, Sharkey WK, et al. Omicron spike 884 function and neutralizing activity elicited by a comprehensive panel of vaccines. Science. 885 886 2022;377(6608):890-4. Epub 20220719. doi: 10.1126/science.abq0203. PubMed PMID: 35857529; PubMed Central PMCID: PMCPMC9348749. 887
- 16. Wang Y, Ma Y, Xu Y, Liu J, Li X, Chen Y, et al. Resistance of SARS-CoV-2 Omicron 888 variant to convalescent and CoronaVac vaccine plasma. Emerg Microbes Infect. 889 2022;11(1):424-7. doi: 10.1080/22221751.2022.2027219. PubMed PMID: 35001836; 890 891 PubMed Central PMCID: PMCPMC8803103.
- 892 17. Khan K, Karim F, Cele S, Reedoy K, San JE, Lustig G, et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature. 2022;607(7918):356-9. Epub 893 894 20220506. doi: 10.1038/s41586-022-04830-x. PubMed PMID: 35523247; PubMed Central PMCID: PMCPMC9279144. 895
- 896 18. Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al. Omicron BA.4/BA.5 897 escape neutralizing immunity elicited by BA.1 infection. Nat Commun. 2022;13(1):4686. 898 Epub 20220810. doi: 10.1038/s41467-022-32396-9. PubMed PMID: 35948557; PubMed 899 Central PMCID: PMCPMC9364294.
- 19. Khan K, Lustig G, Bernstein M, Archary D, Cele S, Karim F, et al. Immunogenicity of 900 901 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and 902 Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2022;75(1):e857-e64. doi: 10.1093/cid/ciab1008. PubMed PMID: 903 34893824; PubMed Central PMCID: PMCPMC8689810. 904
- 20. Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht MA, Lambson 905 906 BE, et al. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector 907 functions in previously vaccinated, but not unvaccinated, individuals. Cell Host Microbe. 2022;30(6):880-6 e4. Epub 20220325. doi: 10.1016/j.chom.2022.03.029. PubMed PMID: 908 35436444; PubMed Central PMCID: PMCPMC8947963. 909
- 21. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A Bivalent Omicron-910 Containing Booster Vaccine against Covid-19. N Engl J Med. 2022;387(14):1279-91. 911 912 Epub 20220916. doi: 10.1056/NEJMoa2208343. PubMed PMID: 36112399; PubMed Central PMCID: PMCPMC9511634. 913
- 22. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. Population 914 915 Immunity and Covid-19 Severity with Omicron Variant in South Africa. N Engl J Med. 916 2022;386(14):1314-26. Epub 20220223. doi: 10.1056/NEJMoa2119658. PubMed PMID: 917 35196424; PubMed Central PMCID: PMCPMC8908853.
- 918 23. Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, et al. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. N 919 920 Engl J Med. 2022;386(10):951-63. Epub 20220119. doi: 10.1056/NEJMoa2116747. 921 PubMed PMID: 35045226; PubMed Central PMCID: PMCPMC8796791.
- 24. Vannice K, Wilder-Smith A, Hombach J. Fractional-Dose Yellow Fever Vaccination -922 923 Advancing the Evidence Base. N Engl J Med. 2018;379(7):603-5. Epub 20180711. doi: 924 10.1056/NEJMp1803433. PubMed PMID: 29995585.
- 25. Kharsany ABM, Cawood C, Khanyile D, Lewis L, Grobler A, Puren A, et al. Community-925 926 based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional 927 household survey. Lancet HIV. 2018;5(8):e427-e37. Epub 20180717. doi:
- 10.1016/S2352-3018(18)30104-8. PubMed PMID: 30021700; PubMed Central PMCID: 928 929 PMCPMC7498647.
- 930 26. UNAIDS. HIV and AIDS Estimates South Africa. 2021. 931 https://www.unaids.org/en/regionscountries/countries/southafrica2021.

medRxiv preprint doi: https://doi.org/10.1101/2023.11.20.23298785; this version posted November 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- 932 27. Karim F, Gazy I, Cele S, Zungu Y, Krause R, Bernstein M, et al. HIV status alters disease 933 severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. Elife. 2021;10. Epub 20211005. doi: 10.7554/eLife.67397. PubMed PMID: 34608862; PubMed 934 935 Central PMCID: PMCPMC8676326.
- 936 28. Geretti AM, Stockdale AJ, Kelly SH, Cevik M, Collins S, Waters L, et al. Outcomes of 937 Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With 938 Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) 939 Clinical Characterization Protocol (UK): A Prospective Observational Study. Clin Infect Dis. 2021;73(7):e2095-e106. doi: 10.1093/cid/ciaa1605. PubMed PMID: 33095853; 940 941 PubMed Central PMCID: PMCPMC7665382.
- 29. Ambrosioni J, Blanco JL, Reyes-Uruena JM, Davies MA, Sued O, Marcos MA, et al. 942 943 Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV. 2021;8(5):e294-944 e305. doi: 10.1016/S2352-3018(21)00070-9. PubMed PMID: 33915101; PubMed Central 945 PMCID: PMCPMC8075775.
- 946 30. Western Cape Department of Health in collaboration with the National Institute for 947 Communicable Diseases SA. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin 948 949 Infect Dis. 2021;73(7):e2005-e15. doi: 10.1093/cid/ciaa1198. PubMed PMID: 32860699; 950 PubMed Central PMCID: PMCPMC7499501.
- 31. Davies MA. HIV and risk of COVID-19 death: a population cohort study from the Western 951 Cape Province, South Africa. medRxiv. 2020. Epub 20200703. doi: 952 10.1101/2020.07.02.20145185. PubMed PMID: 32637972; PubMed Central PMCID: 953 954 PMCPMC7340198.
- 32. Bhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV 955 956 infection and COVID-19 death: a population-based cohort analysis of UK primary care 957 data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021;8(1):e24-e32. Epub 20201211. doi: 10.1016/S2352-3018(20)30305-2. PubMed 958 PMID: 33316211; PubMed Central PMCID: PMCPMC7773630. 959
- 33. Tesoriero JM, Swain CE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, et al. COVID-19 960 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York 961 State. JAMA Netw Open. 2021;4(2):e2037069. Epub 20210201. doi: 962 10.1001/jamanetworkopen.2020.37069. PubMed PMID: 33533933; PubMed Central 963 PMCID: PMCPMC7859843. 964
- 965 34. Spinelli MA, Lynch KL, Yun C, Glidden DV, Peluso MJ, Henrich TJ, et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after 966 967 infection, compared by HIV status: a matched case-control observational study. Lancet HIV. 2021;8(6):e334-e41. Epub 20210429. doi: 10.1016/S2352-3018(21)00072-2. 968 PubMed PMID: 33933189; PubMed Central PMCID: PMCPMC8084354. 969
- 970 35. Walaza S, Tempia S, von Gottberg A, Wolter N, Bhiman JN, Buys A, et al. Risk Factors 971 for Severe Coronavirus Disease 2019 Among Human Immunodeficiency Virus-Infected and -Uninfected Individuals in South Africa, April 2020-March 2022: Data From Sentinel 972 973 Surveillance. Open Forum Infect Dis. 2022;9(12):ofac578. Epub 20221102. doi: 974 10.1093/ofid/ofac578. PubMed PMID: 36570970; PubMed Central PMCID: PMCPMC9772867. 975
- 36. Motsoeneng BM, Manamela NP, Kaldine H, Kgagudi P, Hermanus T, Ayres F, et al. 976 Despite delayed kinetics, people living with HIV achieve equivalent antibody function after 977 978 SARS-CoV-2 infection or vaccination. Front Immunol. 2023;14:1231276. Epub 20230803. 979 doi: 10.3389/fimmu.2023.1231276. PubMed PMID: 37600825; PubMed Central PMCID: 980 PMCPMC10435738.
- 981 37. Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a 982 single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021;8(8):e474-e85. Epub 983 20210618. doi: 10.1016/S2352-3018(21)00103-X. PubMed PMID: 34153264; PubMed 984 985 Central PMCID: PMCPMC8213361.

- 986 38. Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. 987 Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021;27(12):1851-5. Epub 20210824. doi: 988 989 10.1016/j.cmi.2021.07.031. PubMed PMID: 34438069; PubMed Central PMCID: 990 PMCPMC8382485.
- 991 39. Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, et al. 992 The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses 993 in People Living With Human Immunodeficiency Virus (HIV). Clin Infect Dis. 994 2022;74(7):1268-70. doi: 10.1093/cid/ciab648. PubMed PMID: 34293114; PubMed 995 Central PMCID: PMCPMC8406881.
- 40. Ruddy JA, Boyarsky BJ, Bailey JR, Karaba AH, Garonzik-Wang JM, Segev DL, et al. 996 997 Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in 998 persons with HIV. AIDS. 2021;35(14):2399-401. doi: 10.1097/QAD.0000000000003017. PubMed PMID: 34261097; PubMed Central PMCID: PMCPMC10323870. 999
- 41. Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC, et al. Humoral 1000 1001 immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. NPJ Vaccines. 2022;7(1):28. Epub 20220228. doi: 1002 1003 10.1038/s41541-022-00452-6. PubMed PMID: 35228535; PubMed Central PMCID: PMCPMC8885829. 1004
- 1005 42. Saxena M, Van TTH, Baird FJ, Coloe PJ, Smooker PM. Pre-existing immunity against vaccine vectors--friend or foe? Microbiology (Reading). 2013;159(Pt 1):1-11. Epub 1006 20121122. doi: 10.1099/mic.0.049601-0. PubMed PMID: 23175507; PubMed Central 1007 1008 PMCID: PMCPMC3542731.
- 43. Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and 1009 circumvention strategies. Curr Gene Ther. 2011;11(4):307-20. doi: 1010 10.2174/156652311796150372. PubMed PMID: 21453277; PubMed Central PMCID: 1011 PMCPMC4009923. 1012
- 44. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative 1013 immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and 1014 1015 replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1016 1 gag gene. J Virol. 2003;77(11):6305-13. doi: 10.1128/jvi.77.11.6305-6313.2003. PubMed PMID: 12743287; PubMed Central PMCID: PMCPMC154996. 1017
- 45. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, et al. 1018 1019 Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of preexisting anti-Ad5 immunity. J Immunol. 2004;172(10):6290-7. doi: 1020 1021 10.4049/jimmunol.172.10.6290. PubMed PMID: 15128818.
- 46. Shiver JW. Emini EA. Recent advances in the development of HIV-1 vaccines using 1022 1023 replication-incompetent adenovirus vectors. Annu Rev Med. 2004;55:355-72. doi: 1024 10.1146/annurev.med.55.091902.104344. PubMed PMID: 14746526.
- 47. Le Gars M, Sadoff J, Struyf F, Heerwegh D, Truyers C, Hendriks J, et al. Impact of 1025 1026 Preexisting Anti-Adenovirus 26 Humoral Immunity on Immunogenicity of the 1027 Ad26.COV2.S Coronavirus Disease 2019 Vaccine. J Infect Dis. 2022;226(6):979-82. doi: 1028 10.1093/infdis/jiac142. PubMed PMID: 35429381; PubMed Central PMCID: 1029 PMCPMC9047246.
- 48. Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, et al. Safety and 1030 immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola 1031 1032 vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2022;22(1):110-22. Epub 20210913. doi: 10.1016/S1473-1033 3099(21)00128-6. PubMed PMID: 34529962; PubMed Central PMCID: 1034 1035 PMCPMC7613317.
- 49. U.S. Department of Health and Human Services FaDA. Guidance for Industry. Toxicity 1036 Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive 1037 1038 Vaccine Clinical Trials. 2007. https://www.fda.gov/media/73679/download.
- 1039 50. Khoo NKH, Lim JME, Gill US, de Alwis R, Tan N, Toh JZN, et al. Differential 1040 immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine

recipients. Med. 2022;3(2):104-18 e4. Epub 20220119. doi: 10.1016/j.medj.2021.12.004. 1041 PubMed PMID: 35072129; PubMed Central PMCID: PMCPMC8767655. 1042 51. Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, et al. Safety, 1043 reactogenicity, and immunogenicity of homologous and heterologous prime-boost 1044 immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet 1045 Respir Med. 2021;9(11):1255-65. Epub 20210813. doi: 10.1016/S2213-2600(21)00357-X. 1046 PubMed PMID: 34391547; PubMed Central PMCID: PMCPMC8360702. 1047 52. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S, et al. Immunogenicity and 1048 reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 1049 1050 2021;27(9):1530-5. Epub 20210726. doi: 10.1038/s41591-021-01464-w. PubMed PMID: 34312554; PubMed Central PMCID: PMCPMC8440177. 1051 53. Irrgang P, Gerling J, Kocher K, Lapuente D, Steininger P, Habenicht K, et al. Class switch 1052 toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 1053 mRNA vaccination. Sci Immunol. 2023;8(79):eade2798. Epub 20230127. doi: 1054 10.1126/sciimmunol.ade2798. PubMed PMID: 36548397; PubMed Central PMCID: 1055 1056 PMCPMC9847566. 54. Buhre JS, Pongracz T, Kunsting I, Lixenfeld AS, Wang W, Nouta J, et al. mRNA vaccines 1057 1058 against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-1059 based vaccine. Front Immunol. 2022;13:1020844. Epub 20230112. doi: 1060 10.3389/fimmu.2022.1020844. PubMed PMID: 36713457; PubMed Central PMCID: 1061 1062 PMCPMC9877300. 55. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial 1063 translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 1064 2006;12(12):1365-71. Epub 20061119. doi: 10.1038/nm1511. PubMed PMID: 17115046. 1065 1066 56. Jedicke N, Stankov MV, Cossmann A, Dopfer-Jablonka A, Knuth C, Ahrenstorf G, et al. Humoral immune response following prime and boost BNT162b2 vaccination in people 1067 1068 living with HIV on antiretroviral therapy. HIV Med. 2022;23(5):558-63. Epub 20211102. doi: 10.1111/hiv.13202. PubMed PMID: 34725907; PubMed Central PMCID: 1069 1070 PMCPMC8652991. 1071 57. Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, et al. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute 1072 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human 1073 Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-1074 Lymphocyte Count. Clin Infect Dis. 2022;75(1):e552-e63. doi: 10.1093/cid/ciac238. 1075 1076 PubMed PMID: 35366316; PubMed Central PMCID: PMCPMC9047161. 58. Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, et al. 1077 Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV. Nat 1078 1079 Commun. 2022;13(1):4922. Epub 20220822. doi: 10.1038/s41467-022-32263-7. PubMed PMID: 35995780; PubMed Central PMCID: PMCPMC9395398. 1080


medRxiv preprint doi: https://doi.org/10.1101/2023.11.20.23298785; this version posted November 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .


	Arm A Full-dose Ad26.COV2.S	Arm B Half-dose Ad26.COV2.S	Arm C Full-dose BNT162b2	Arm D Half-dose BNT162b2	Total
Vaccinated (N)	74	69	73	73	289
Age*	42 (35-48)	40 (35-45)	43 (35-50)	42 (35-49)	42 (35-49)
18-29 years	5 (6.8%)	5 (7.2%)	7 (9.6%)	6 (8.2%)	23 (8%)
30-44 years	41 (55.4%)	46 (66.7%)	34 (46.6%)	34 (46.6%)	155 (53.6%)
45-54 years	20 (27%)	10 (14.5%)	23 (31.5%)	22 (30.1%)	75 (26%)
≥ 55 years	8 (10.8%)	8 (11.6%)	9 (12.3%)	11 (15.1%)	36 (12.5%)
Sex					
Male	10 (13.5%)	8 (11.6%)	18 (24.7%)	15 (20.5%)	51 (17.6%)
Female	64 (86.5%)	61 (88.4%)	55 (75.3%)	58 (79.5%)	238 (82.4%)
Ethnicity					
Black African	69 (93.2%)	67 (97.1%)	69 (94.5%)	70 (95.9%)	275 (95.2%)
Other	5 (6.8%)	2 (2.9%)	4 (5.5%)	3 (4.1%)	14 (4.8%)
Days between prime and Booster*	265 (245-292)	271 (259-302)	273 (258-291)	272 (253-300)	271 (255-296)
BMI					
Underweight	0 (0%)	2 (2.9%)	0 (0%)	1 (1.4%)	3 (1%)
Normal	12 (16.2%)	8 (11.6%)	14 (19.2%)	6 (8.2%)	40 (13.8%)
Overweight	20 (27%)	41 (59.4%)	39 (53.4%)	47 (64.4%)	71 (24.6%)
Obese	41 (55.4%)	39 (56.5%)	47 (64.4%)	47 (64.4%)	174 (60.2%)
Not available	1 (1.4%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
HIV infection					
HIV Positive	27 (36.5%)	28 (40.6%)	31 (42.5%)	30 (41.1%)	116 (40.1%)
Viremic <sup>\$</sup> CD4 count (cells/mm <sup>3</sup> )* Viral load (copies/mL)* Aviremic <sup>\$</sup> CD4 count (cells/mm <sup>3</sup> )*	1 (3.7%) 223 (na) 818 na 26 (96.3%) 698 (580-923)	5 (17.9%) 452 (103-471) 5838 (3054-18252) 23 (82.1%) 677 (530-855)	4 (12.9%) 1136 29911 (14863-47207) 27 (87.1%) 812 (623-931	6 (20%) 341 (132-538) 19960 (5324-37713) 24 (80%) 666 (538-737)	16 (13.8%) 452 (132-538) 15376 (3054-27420) 100 (86.2%) 708 (558-922)
Prior SARS-CoV-2 infection <sup>&amp;</sup>	51/58 (87.8%)	52/57 (91.2%)	55/59 (93.2%)	55/59 (93.2%)	213/223 (91.4%)
Co-morbidities	, ,	, ,	, ,	, ,	· · · · · · · · · · · · · · · · · · ·
Hypertension	19 (25.7%)	8 (11.6%)	17 (23.3%)	17 (23.3%)	61 (21.1%)
Anaemia	7 (9.5%)	8 (11.6%)	6 (8.2%)	9 (12.3%)	30 (10.4%)
Asthma	6 (8.1%)	3 (4.3%)	2 (2.7%)	1 (1.4%)	12 (4.2%)
Diabetes mellitus	3 (4.1%)	1 (1.4%)	4 (5.5%)	4 (5.5%)	12 (4.2%)
Arthritis	1 (1.4%)	0 (0%)	3 (4.1%)	3 (4.1%)	7 (2.4%)
Tuberculosis	0 (0%)	4 (5.8%)	2 (2.7%)	0 (0%)	6 (2.1%)
Retention					
W2 visits completed	74 (100%)	66 (95.7%)	72 (98.6%)	69 (94.5%)	281 (97.2%)
W12 visits completed	74 (100%)	67 (97.1%)	67 (91.8%)	70 (95.9%)	278 (96.2%)
W24 visits completed	69 (93.2%)	63 (91.3%)	69 (94.5%)	68 (93.2%)	269 (93.1%)


#### Table 1: Clinical Characteristics of study participants


Unless specified, all data are presented as n (%N); \*median and interquartile range (IQR); \$% is of all HIV-infected participants; Viremic individuals were defined as having a HIV-1 viral load (VL) >200 HIV mRNA copies/mm<sup>3</sup>; 3 participants in the viremic arm C had a missing CD4 count; <sup>&</sup>Prior SARS-CoV-2 infection was defined by the presence of Nucleocapsid-specific IgG; na: non-applicable.


Table 1















## Figure 5





# Figure 7















1	-	Spike-sp CE	04 T cell (%)	Spike-sp CE	08 T cell (%)	FC Spike CD4
		BL	W2	BL	W2	W2 vs BL
	Ad26-sp CD4 T cells (%) at BL	p = 0.11 r = 0.24	p = 0.25 r = 0.18	p = 0.05 r = 0.30	p = 0.16 r = 0.29	p = 0.08 r = -0.27
	Ad26-sp CD8 T cells (%) at BL	p = 0.001 r = 0.47	p = 0.016 r = 0.37	p = 0.007 r = 0.40	p = 0.009 r = 0.39	p = 0.037 r = -0.32



Supplemental Figure 1: SARS-CoV-2 spike-specific T cell responses in participants stratified by HIV status in each study arm. Frequency of spike-specific CD4+ T cells (A) and spike-specific CD8+ T cells (B) before (BL) and 2 weeks after vaccine boost (W2) in HIV-negative participants and in PLWH. Bars represent medians. Viremic PLWH are identified with a cross. Bars represent medians. A two-tailed Wilcoxon signed-rank test was used to assess statistical differences between paired samples and a Kruskal-Wallis with Dunn's corrections was used to compare different groups.

### Supp Table 1

	Vax-naive	J&J primed	J&J boosted
N	14	14	6
Age*	46 (37-57)	46 (37-57)	55 (49-57)
Gender (% female)	100%	100%	100%
Time since last vaccination (days)*	na	44 (31-53)	110 (96-117)

Supplementary Table 1: Clinical characteristics of samples used for Ad26specific antibody response assessment. (Related to Figure 10F). \*: Median and Interquartile range (IQR), na: not applicable.

### Supp Table 2

	Vax-naive	J&J primed
Ν	20	11
Age*	43 (33-53)	49 (32-53)
Gender (% female)	90%	81.8%
Time since vaccination (days)*	na	25 (20-45)

**Supplementary Table 2: Clinical characteristics of samples used for Ad26-specific T cell response assessment.** (Related to Figures 11D and 11G). All participants were HIV-uninfected. \*: Median and Interquartile range (IQR). na: not applicable.